Raz R, Boger S
Infectious Disease Unit, Central Emek Hospital, Afula, Israel.
Antimicrob Agents Chemother. 1991 Jun;35(6):1241-2. doi: 10.1128/AAC.35.6.1241.
A total of 102 women with recurrent urinary tract infections were included in this open randomized study; 55 received 200 mg of norfloxacin daily and 47 received 50 mg of nitrofurantoin daily over 6 months. Fifty-three and 41 women from the norfloxacin- and nitrofurantoin-treated groups, respectively, completed the 6-month follow-up period. Forty-four (81%) of the norfloxacin-treated patients and 27 (65%) of the nitrofurantoin-treated patients remained free of symptoms (P = 0.05), and urine samples from 49 (92.4%) and 29 (70.7%) of the patients, respectively, were sterile (P less than 0.005). Side effects occurred with similar frequencies in both groups (15 and 17%) but were more severe in the women who received nitrofurantoin. Despite the better results obtained with norfloxacin, the difference in the costs of the two agents must be considered.
这项开放性随机研究共纳入了102名复发性尿路感染女性患者;55名患者每日服用200毫克诺氟沙星,47名患者在6个月内每日服用50毫克呋喃妥因。诺氟沙星治疗组和呋喃妥因治疗组分别有53名和41名女性完成了6个月的随访期。诺氟沙星治疗的患者中有44名(81%)、呋喃妥因治疗的患者中有27名(65%)无症状(P = 0.05),两组患者的尿样分别有49名(92.4%)和29名(70.7%)无菌(P小于0.005)。两组副作用发生频率相似(分别为15%和17%),但在服用呋喃妥因的女性中副作用更严重。尽管诺氟沙星取得了更好的效果,但必须考虑两种药物的成本差异。